ATS 2020 Advance Program

highly interactive session will provide a multi-disciplinary approach to the diagnosis and treatment of environmental and occupational lung diseases, teach clinicians about environmental contributors to common lung diseases, and update the audience on emerging exposure-related lung diseases. Chairing: P.S. Lai, MPH, MD, ATSF, Boston, MA M.E. Rebuli, PhD, Chapel Hill, NC J.J. Rose, MD, MBA, Pittsburgh, PA 8:00 Opening Remarks P.S. Lai, MPH, MD, ATSF, Boston, MA 8:05 How Do I Ask? A Clinician’s Approach S.D. Krefft, MD, MPH, Denver, CO 8:40 Workers Compensation: How Do I Establish Causation? D.C. Christiani, MD, MPH, MS, ATSF, Boston, MA 9:15 How Will Imaging Help? A Radiologist’s Approach S. Hobbs, MD, Lexington, KY 9:50 Wheezing on the Job: Work-Related Asthma S.M. Tarlo, MBBS, Toronto, Canada 10:25 Break 10:35 Hypersensitivity Pneumonitis: Difficult to Diagnose, Often Harder to Treat K.A.M. Johannson,MD,MPH, ATSF,Calgary,Canada 11:10 The Lingering Effects of Military Deployment C.S. Rose, MD, MPH, Denver, CO 11:45 Are e-Cigarettes Really Better than Tobacco? J.E. Gotts, MD, PhD, San Francisco, CA 12:20 LUNCH 12:50 Doc Is It My Microbiome? P.S. Lai, MPH, MD, ATSF, Boston, MA 1:25 Eating Our Way to Lung Health: The Impact of Diet on Lung Disease P. Hansbro, PhD, Sydney, Australia 2:00 How Can My Patients Protect Themselves Against Air Pollution? R.J. Laumbach, MD, MPH, Piscataway, NJ 2:35 Break 2:45 Carbon Monoxide: The Silent Killer J.J. Rose, MD, MBA, Pittsburgh, PA 3:20 Inhalational Disasters: Are We Ready? E.R. Svendsen, PhD, Atlanta, GA 3:55 Closing Remarks M.E. Rebuli, PhD, Chapel Hill, NC CLINICAL POSTGRADUATE COURSE PG21 ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF PEDIATRIC SEVERE ASTHMA Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 Assembly on Pediatrics 8:00 a.m. - 4:00 p.m. Target Audience Providers caring for children with severe asthma Objectives At the conclusion of this session, the participant will be able to: • perform a stepwise evaluation for pediatric patients referred for severe asthma; • list biomarkers for asthma and describe their role in the asthma inflammatory pathways; • choose biologic or advanced non-T2 directed therapies for patients with severe asthma who have not responded to standard therapies. This course provides state of the art information on the evaluation and management of severe asthma in children. The focus of this course will be to synthesize recent advances in the field, focusing on newly available biologic treatments and work targeting novel pathways for new therapies. Speakers will review best practices for evaluation including medication adherence monitoring and support. They will ATS 2020 • Philadelphia, PA SATURDAY • MAY 16 25